The 6.64% growth priced into TXN requires capital that destroys 43 cents per dollar at 3.9% ROIC.
The market prices TXN for recovery while fundamentals show accelerating deterioration in capital efficiency despite margin improvements.
What expectations are embedded in the price, and are they reasonable?
This framework sees the market pricing recovery that the fundamentals contradict. The implied 6.64% growth appears conservative versus trailing 13%, but at 33.9x earnings with ROIC below cost of capital, even modest growth expectations seem unreasonable.
Is the business creating or destroying value?
Applying this lens reveals sustained value destruction. The 62% ROIC collapse while margins recovered suggests the business is consuming more capital to generate each dollar of profit—a structural deterioration masked by operational improvements.
Is growth creating or destroying value?
This framework identifies value-destroying growth—revenue expansion requiring disproportionate capital investment. The negative spread between ROIC and WACC means each dollar of growth funded by 98th percentile leverage reduces shareholder value.
Does this company have structural reasons to defy mean reversion?
Base rates suggest further margin compression ahead. The 0th percentile gross margin combined with peak leverage and no structural moat makes this a classic mean reversion candidate where today's 33% operating margins likely overshoot to the downside.
Applying this framework reveals a business where the market's recovery expectations clash with accelerating capital efficiency deterioration. The 33.9x multiple prices in growth that destroys value at current returns, while base rates and the 0th percentile gross margin suggest further compression ahead. Insider buying of $102M represents a bet against this framework's conclusions. Is management seeing a cyclical trough or are they fighting structural decline?
This analysis applies Michael Mauboussin's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Michael Mauboussin. Educational purposes only. Not financial advice.